TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Jedd D Wolchok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.